Prostate Specific Antigen News and Research

RSS

Intermittent hormone therapy effective for prostate cancer patients

Intermittent androgen deprivation is as effective as continuous therapy for men with rising prostate-specific antigen levels after primary or salvage radiotherapy, say researchers who believe the break from treatment improves quality of life.

10 Sep 2012

PRISM technique as accurate as ELISAs in identifying proteins within biological samples

Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online.

4 Sep 2012

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Sophiris Bio Inc. today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

1 Sep 2012

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

n order to find out what kind of doctor patients were visiting for primary care service, researchers analyzed the frequency in which patients visited generalists and specialists in 1999 and 2007 by using a nationally representative sample of outpatient visits.

26 Aug 2012

Survival rate for African-American men with prostate cancer now comparable to Caucasians

The routine use of prostate specific antigen (PSA) testing for screening and monitoring prostate cancer has led to early and more sensitive detection of the disease. A new study published in The Journal of Urology- reports that in the "PSA era," survival has improved for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body and the disparity between African American and Caucasian men has been resolved.

24 Aug 2012

Six common myths about prostate cancer

When it comes to prostate cancer, there's a lot of confusion about how to prevent it, find it early and the best way - or even whether - to treat it. Below are six common prostate cancer myths along with research-based information from scientists at Fred Hutchinson Cancer Research Center to help men separate fact from fiction.

23 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

Safety net hospitals prepare for changes from health law; Patients hesitant to challenge doctors

Safety-net hospitals – which often provide care to low-income and uninsured populations – are facing reduced federal and state support for uncompensated care under the Affordable Care Act. However, this study points out that 23 million people will remain uninsured and continue to need care from the hospitals.

18 Aug 2012

Therapeutic breaks for prostate cancer patients

Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.

15 Aug 2012

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.

15 Aug 2012

Combination of novel drug therapy and PSA test can effectively detect prostate cancer

Researchers have successfully developed and tested a new prostate cancer screening method that uses the combined power of a novel drug therapy and changes in PSA levels over time to identify men with a high PSA who are more likely to have aggressive prostate cancer despite negative biopsies.

12 Aug 2012

Researchers develop and test new prostate cancer screening method

9 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Simpler and more accurate way to test for prostate cancer

An undergraduate student's technique for detecting certain metabolites in urine samples could lead to a simpler and more accurate way to test for prostate cancer.

3 Aug 2012

Men with large waists urinate more frequently than their slimmer counterparts

Men with large waists urinate more frequently than their slimmer counterparts, according to research in the August issue of the urology journal BJUI.

31 Jul 2012

PSA testing and early detection may prevent 17,000 men each year from prostate cancer

A new analysis has found that doing away with PSA (prostate specific antigen) testing for prostate cancer would likely cause three times as many men to develop advanced disease that has spread to other parts of the body before being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study suggests that PSA testing and early detection may prevent approximately 17,000 men each year from having such advanced prostate cancer at diagnosis.

30 Jul 2012

Healthcare system perceptions predict PSA screening uptake

Study findings suggest that African–American and Afro–Caribbean men who have poor perceptions or experiences of their healthcare system are less likely to have prostate-specific antigen screening than those with positive healthcare experiences.

25 Jul 2012

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.

24 Jul 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

Beckman Coulter announces PMA from FDA for Prostate Health Index

Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.

From Beckman Coulter Diagnostics 26 Jun 2012